Pregabalin versus gabapentin in partial epilepsy: a meta-analysis of dose-response relationships

BMC Neurology

Table 1 Summary of the multicenter, double-blind, randomized placebo-controlled trials included in the base-case and sensitivity analyses.

Individual Studies
Pregabalin Trials	Daily Dose (Titration Period)	No. of Patients		Gabapentin Trials	Daily Dose (Titration Period)	No. of Patients
		ITT	Completers			ITT	Completers
Beydoun et al 2005 [21] (Study 1008-009)	600 mg (1 week)	214	156	UK Gabapentin Study Group, 1990 [27] (Study 877-210P)	1200 mg (2 weeks)	61	54
	Placebo	98	81		Placebo	66	61
Arroyo et al 2004 [20] (Study 1008-011)	150 mg (3 days)	99	88	The US Gabapentin Study Group No. 5, 1993 [26] (Study 945-5)^d	1200 mg (2-3 days)	101	95
	600 mg (1 week)	92	69		1800 mg (2-3 days)	54	53
	Placebo	96	84		Placebo	98	96
French et al 2003 [23] (Study 1008-034)^a,b	150 mg	86	81	Anhut et al 1994 [24] (Study 945-6)	900 mg (2 days)	109	100
	300 mg	90	71
	600 mg	89	61		1200 mg (2 days)	52	50
	Placebo	100	87		Placebo	109	100
Elger et al 2005 [22] (Study 1008-157)^b,c	600 mg	137	80	Sivenius et al 1991 [25] (Study 945-9/10)	900 mg (2 days)	36	32
					1200 mg (2 days)	17	16
	Placebo	73	56		Placebo	34	30
Aggregated Studies
Treatment in Pregabalin Trials	Daily Dose	No. of Patients		Treatment in Gabapentin Trials	Daily Dose	No. of Patients
		ITT	Completers			ITT	Completers
Placebo		367	308	Placebo		307	287
Low-Dose Pregabalin	150 mg	185	169	Low-Dose Gabapentin	900 mg	145	132
Mid-Dose Pregabalin	300 mg	90	71	Mid-Dose Gabapentin	1200 mg	231	215
High-Dose Pregabalin	600 mg	532	366	High-Dose Gabapentin	1800 mg	54	53

All studies had a 12-week double-blind maintenance phase but the durations of the titration phases were variable.
^aIn addition to the doses listed above, for trial 1008-034 patients were also recruited into a 50 mg dose group. This dose was not found to be therapeutic and is not registered for use in Australia.
^bNo titration phase.
^cIn addition to the doses listed above, for trial 1008-157 patients were also recruited into a titrated dose arm with total daily doses ranging from 150 mg to 600 mg, depending on individual requirement. This treatment group was not comparable with the other fixed-dose treatment groups and was excluded from the analyses.
^dIn addition to the doses listed above, for trial 945-5 patients were also recruited into a 600 mg dose group. This dose was not found to be therapeutic and is not registered in Australia.
ITT = intention-to-treat.

ISSN: 1471-2377